Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
WULF$11.93-0.61(-4.86%)TeraWulf Falls 4% Despite Google Backstop for $19 Billion Anthropic Leases; Cipher Digital Plunges 18%, IREN Tumbles 9%12:56:12 PM ETDELL$374.45-33.81(-8.28%)Super Micro Falls 4% Despite Blowout Quarter as Margin Worries and Data Center Backlash Weigh; Dell Sinks 8%, Hewlett Packard Enterprise Drops 6%12:51:48 PM ETNVO$42.96+2.76(+6.87%)Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone12:47:46 PM ETAMD$485.67+1.84(+0.38%)Nvidia is Far From The Only Threat to AMD12:45:28 PM ETGOOG$290.52+12.23(+4.39%)Alphabet's Asymmetry Is All You Need To Know About to Hit ‘Buy'12:45:18 PM ETGOOG$290.52+12.23(+4.39%)Watch out for Big Tech companies like Meta and Alphabet issuing more shares and diluting your stock ownership12:44:00 PM ETTSLA$390.64-7.70(-1.93%)Why Shares of Elon Musk's Tesla, SpaceX Are Sliding After the Midterm Elections12:42:13 PM ETAAPL$354.06+22.42(+6.76%)Apple's Pain Could Be Micron's Gain as Memory Prices Surge12:33:14 PM ETAAPL$354.06+22.42(+6.76%)Apple Rallies as Big Tech Comes Back: What It Means for Your Index Fund12:33:00 PM ETCRWD$242.80-1.84(-0.75%)CrowdStrike Launches Sovereign Cloud in Saudi Arabia, Bringing AI-Native Cybersecurity to the Kingdom12:28:00 PM ETAAPL$354.06+22.42(+6.76%)Apple stock hit a new all-time high on Wednesday: what's fuelling the rally?12:18:17 PM ETAMZN$269.32+18.54(+7.39%)Amazon Surges After Democrats Take Congress. Here's Which ETFs Feel It Most12:06:31 PM ETSPCX$136.72-4.61(-3.26%)SpaceX: Super Intelligence Segment Turns It Into An AI Infrastructure Heavyweight12:05:26 PM ETNFLX$66.17+2.80(+4.42%)Netflix Is Playing a Bigger Game. Investors Should Take Notice12:03:26 PM ETACN$264.77+10.21(+4.01%)Accenture vs. Oracle: Which Technology Stock Is a Better Buy in 2027?12:00:02 PM ETBRK-A$860,033.84+23,903.55(+2.86%)Berkshire Hathaway Buys More Sirius XM, Sending Stock to 52-Week High11:56:00 AM ETNVDA$203.30-3.26(-1.58%)Can NVDA Stock Jump From Here?11:55:23 AM ETPLTR$170.84-4.50(-2.57%)Why Palantir Technologies Stock Dropped Today11:46:23 AM ETTSLA$390.64-7.70(-1.93%)Tesla's Five Year Stock Price Turns Negative11:46:03 AM ETSHOP$151.48+8.77(+6.15%)Cathie Wood Bought $12.5 Million of Shopify as It Tanked11:37:31 AM ETTSLA$390.64-7.70(-1.93%)Musk's Election Bet Backfires on Tesla, and Your Index Fund Owns a Piece of It11:33:41 AM ETINTC$58.80-1.70(-2.81%)Intel Just Delivered Its Strongest Data Center Growth in 15 Years. Its Comeback Is Gaining Momentum11:33:28 AM ETAMD$485.67+1.84(+0.38%)AMD Rallies After Chipmaker "Beat Where It Mattered" in Earnings11:30:19 AM ETWMT$130.16+5.32(+4.26%)Walmart's Dec. 11 Dividend Isn't the Real Reason to Own the Stock11:30:00 AM ET

VALN · NASDAQ

Valneva SE

$5.77 +0.29 (+5.29%)

Company overview

Valneva SE, a specialty vaccine company, focuses on developing and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin-producing Enterotoxigenic Escherichia coli; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trials against Borrelia, and VLA1553, a vaccine candidate in Phase III clinical trials against the chikungunya virus.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$547M
Employees
713
Headquarters
Saint-Herblain
Website
valneva.com
CEO
Thomas Lingelbach
Listed
May 5, 2021
P/E
-3.54
Dividend yield
0.00%

Company financials

Revenue
$156M
Gross profit
$46.1M
Operating income
-$99.4M
EBITDA
-$96.6M
Net income
-$138M
EPS
-$1.63
Total assets
$372M
Total debt
$210M
Gross margin
29.46%
Net margin
-88.30%
Earnings yield
-28.25%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

4.655.346.036.727.41
VALN 1D NASDAQ O5.43H5.57L5.43C5.48+0.16 (+3.01%)Vol3.48K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
VALNValneva SE Press release Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 GlobeNewswire
VALNValneva SE Press release Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences GlobeNewswire
VALNValneva SE Press release Valneva Provides Update on IXCHIQ® in the United Kingdom GlobeNewswire
VALNValneva SE Stock news Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN) Defense World
VALNValneva SE Stock news Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN) Defense World
VALNValneva SE Stock news Applied Optoelectronics, SanDisk, Seagate And Other Big Stocks Moving Lower In Monday's Pre-Market Session Benzinga
VALNValneva SE Stock news Valneva: The Lyme Royalty Transition Changes The Earnings Model Seeking Alpha
VALNValneva SE Stock news European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application Benzinga
VALNValneva SE Stock news Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency GuruFocus
VALNValneva SE Press release Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency GlobeNewswire
VALNValneva SE Stock news Valneva SE (VALN) Q2 2026 Earnings Call Transcript Seeking Alpha
VALNValneva SE Stock news Valneva Q2 Earnings Call Highlights MarketBeat
VALNValneva SE Press release Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités GlobeNewswire
VALNValneva SE Press release Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates GlobeNewswire
VALNValneva SE Press release Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 GlobeNewswire
VALNValneva SE Stock news Valneva to Participate at U.S. and European Investor Conferences in June GlobeNewswire
VALNValneva SE Stock news Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe GlobeNewswire
VALNValneva SE Press release Valneva to Participate at U.S. and European Investor Conferences in June GlobeNewswire
VALNValneva SE Stock news Valneva Q1 Earnings Call Highlights MarketBeat
VALNValneva SE Stock news Valneva SE (VALN) Q1 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about Valneva SE

What does Valneva SE do?
Valneva SE, a specialty vaccine company, focuses on developing and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin-producing Enterotoxigenic Escherichia coli; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trials against Borrelia, and VLA1553, a vaccine candidate in Phase III clinical trials against the chikungunya virus.
What is VALN's market cap?
Valneva SE (VALN) is a listed stock with a live quote. The latest market cap on this page is $547M.
Where is Valneva SE headquartered?
Valneva SE is headquartered in Saint-Herblain.
How do I get VALN news from the API?
Call GET /v1/news?tickers=VALN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does VALN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VALN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the VALN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs